Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Customers experience optimized facility equipment ...
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...
Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...
One-Time Therapeutics Player Bets Future on Working as Supplier to Bioprocess Companies Repligen, once a strongly focused therapeutics firm, has transformed itself into a bioprocess products company ...
Repligen reported third-quarter revenue of $24.7 million. That's better than Wall Street expected and represents a 25% year-over-year increase. CEO Tony Hunt said that this impressive growth stemmed ...
WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results